Etamsylate: Uses & Dosage | MIMS Hong Kong

This information is not country-specific. Please refer to the Hong Kong prescribing information.

Generic Medicine Info

Indications and Dosage

Intramuscular, Intravenous
Capillary haemorrhage

Adult: As treatment or prevention: 500-750 mg tid.

Intramuscular, Intravenous
Diffuse perioperative haemorrhage

Adult: As prevention and treatment: Preoperative: 500 mg given 1 hour before surgery. Postoperative: 250 mg bid.

Contraindications

Hypersensitivity. Bronchial asthma, acute porphyria.

Special Precautions

Patient with hypotension or unstable blood pressure. Pregnancy and lactation.

Adverse Reactions

Significant: Severe hypersensitivity reactions (including anaphylaxis), hypotension.
Blood and lymphatic system disorders: Rarely, neutropenia, agranulocytosis, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort.
General disorders and administration site conditions: Asthenia. Rarely, fever.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Rarely, thromboembolism.

Action

Description:
Mechanism of Action: Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
Synonym(s): Ethamsylate.
Pharmacokinetics:
Absorption: Slowly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 4-5 hours.
Distribution: Crosses the placenta and enters breast milk. Volume of distribution: 86.6 L. Plasma protein binding: Approx 90-95%.
Excretion: Via urine (approx 72% as unchanged drug). Elimination half-life: 2 hours (IV).

Chemical Structure

Storage

Store below 30°C. Protect from light.

MIMS Class

Haemostatics

ATC Classification

B02BX01 - etamsylate ; Belongs to the class of other systemic hemostatics. Used in the treatment of hemorrhage.

References

Brayfield A, Cadart C (eds). Etamsylate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/02/2026.

Etamsylate. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/02/2026.

Disclaimer: This information is independently developed by MIMS based on Etamsylate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2026 MIMS. All rights reserved. Powered by MIMS.com